资讯

Pharmabiz7 小时
Boehringer Ingelheim begins THULITE phase II study of BI 1815368, a potential oral ...
Ingelheim, Germany Tuesday, July 8, 2025, 14:00 Hrs [IST] ...
Ophthalmology Times4 小时
Boehringer Ingelheim launches phase 2 study of oral therapy for diabetic macular edema
Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...